Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Castle Biosciences Inc CSTL

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. It... see more
< Previous
Next >

Current News (NDAQ:CSTL)

Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma

Business Wire 1 day ago

Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry

Business Wire 7 days ago

TissueCypher® Barrett's Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett's Esophagus

Business Wire 12 days ago

Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory

Business Wire September 12, 2023

Integrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences' IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe Depression

Business Wire September 9, 2023

TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett's Esophagus

Business Wire September 8, 2023

Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023

Business Wire September 6, 2023

Castle Biosciences to Participate in Upcoming Investor Conferences

Business Wire September 5, 2023

New Publication Highlights the Ability of the TissueCypher® Barrett's Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett's Esophagus

Business Wire August 7, 2023

Opinion & Analysis (NDAQ:CSTL)

Castle Biosciences Shares Storm Higher After Quadrupling Q3 YoY Revenue

Streetwise Reports November 13, 2019

Bullboard Posts (NDAQ:CSTL)